Scissortail Wealth Management LLC purchased a new stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 8,900 shares of the company’s stock, valued at approximately $598,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. Fairfield Bush & CO. acquired a new stake in shares of AstraZeneca in the second quarter valued at about $25,000. ICA Group Wealth Management LLC acquired a new position in AstraZeneca during the fourth quarter worth approximately $26,000. Anchor Investment Management LLC acquired a new position in AstraZeneca during the fourth quarter worth approximately $26,000. Parkside Financial Bank & Trust increased its position in AstraZeneca by 4,875.0% during the first quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock worth $26,000 after buying an additional 390 shares during the last quarter. Finally, Compagnie Lombard Odier SCmA acquired a new position in AstraZeneca during the fourth quarter worth approximately $27,000. Institutional investors and hedge funds own 20.35% of the company’s stock.
AstraZeneca Price Performance
NASDAQ AZN traded up $0.16 on Wednesday, hitting $68.43. 493,757 shares of the company’s stock were exchanged, compared to its average volume of 6,160,067. The stock has a 50-day moving average of $65.98 and a 200-day moving average of $65.83. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.57. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $76.56. The stock has a market cap of $212.16 billion, a price-to-earnings ratio of 35.55, a P/E/G ratio of 1.26 and a beta of 0.50.
AstraZeneca Increases Dividend
The business also recently disclosed a Semi-Annual dividend, which was paid on Monday, March 25th. Investors of record on Friday, February 23rd were issued a $0.965 dividend. This represents a yield of 2.3%. This is an increase from AstraZeneca’s previous Semi-Annual dividend of $0.47. The ex-dividend date of this dividend was Thursday, February 22nd. AstraZeneca’s dividend payout ratio is presently 100.52%.
Analysts Set New Price Targets
A number of equities analysts have weighed in on AZN shares. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday. Jefferies Financial Group downgraded AstraZeneca from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. Finally, Morgan Stanley began coverage on AstraZeneca in a research report on Tuesday, January 23rd. They issued an “overweight” rating on the stock. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $80.00.
View Our Latest Report on AstraZeneca
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Stories
- Five stocks we like better than AstraZeneca
- Russell 2000 Index, How Investors Use it For Profitable Trading
- ASML Fires Warning Shot For Tech Investors
- How is Compound Interest Calculated?
- Prologis Stock Leading U.S. Logistics Boom
- Investing in Travel Stocks Benefits
- Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.